TWO Medical's Advisory Board
Dr Gavin Barlow - Clinical Advisor
Gavin qualified in Medicine at Leicester University, UK in 1993 and subsequently trained in infectious diseases and general internal medicine in Leeds, Sheffield and Dundee, including a two-year research training fellowship at the University of Dundee.
He was appointed consultant physician in infectious diseases/general medicine at Hull & East Yorkshire Hospitals NHS Trust and Honorary Senior Clinical Lecturer at the Hull York Medical School in 2004. He has developed a highly regarded antibiotic stewardship programme, which has contributed to a large decline in healthcare associated MRSA bacteraemia and Clostridium difficile associated diarrhoea in Hull as well as developing new orthopaedic infection, outpatient parenteral antibiotic therapy (OPAT) and bacteraemia/infection consultation services.
His main clinical interests are the management of bacteraemia, complex bacterial and healthcare-associated infection, orthopaedic infection, and OPAT. He has recently published original articles on prognostic scores in community-acquired pneumonia, the epidemiology of community-associated MRSA, and the clinical usefulness of staphylococcal antibody tests. He was awarded Fellowship of the Royal College of Physicians, London in 2009, is a British Society for Antimicrobial Chemotherapy (BSAC) council member and is the department’s clinical governance lead.
Dr Chris Herbert - Business Development Advisor
Chris is the Business Development Manager for Medipex which he joined in January 2006 having previously worked as a research scientist for a spin-out biotechnology company based in Oxfordshire developing "stealth viruses" for gene therapy.
Chris obtained his PhD from Liverpool University where he had been working in the Royal Liverpool University Hospital Department of Surgery studying the transcriptional regulation of a metastasis-associated gene in pancreatic cancer. His BSc in Molecular Biology was also gained at Liverpool University.
Chris has attended a number of seminars regarding business development and technology commercialisation, and in 2004 successfully completed the “Building a Business” course run at the Saïd Business School in Oxford.
Dr Paul Humphreys - Standards and Product Testing Advisor
Paul is Senior Lecturer in Microbiology at the University of Huddersfield where he runs the University’s Hygiene and Disinfection Centre.
The Centre is an industry focussed research group providing product development and testing services for disinfectants and hand sanitisers employing a range of European and International standards. The Centre specialises in the development and validation of sporicides, biocidal wipes and hand sanitisers and has developed a range of rapid screening techniques to optimise product development.
Paul has worked with a wide range of industry partners to develop novel, effective products a number of which have successfully negotiated the transition from concept to commercialisation.
Dr Anthony Lockett - Regulatory Advisor
Tony graduated in Medicine from Newcastle University and worked in Infectious Disease units in Liverpool before joining the Public Health Laboratory Service in Newcastle and Watford. He gained his MSc – with Distinction – from the London School of Hygiene and Tropical Medicine, where he was Lecturer in Microbiology. He was involved in projects in East Africa before joining the pharmaceutical industry, where he worked in antimicrobial development for several large companies. In 1995 he joined the Department of Health in the UK and in 1998 he was awarded a PhD in healthcare economics with a thesis on medical decision making from St Andrews University. In 1998 he joined Covance as a research physician/Director of Heath Care Economics where he remained until 2004, specialising in market orientated clinical and regulatory development planning for pharmaceutical and device companies. In 2004 Tony left Covance to establish ICO Ltd, a pharmaceutical/medical device consultancy. This practice has a special interest in infectious diseases and has made significant contributions to the regulatory and clinical strategies for products in:
- Medical countermeasures for Biological-Based Weapons of Mass Destruction
- New treatments for Malaria
- Development of Metal-based antimicrobials for internal and surface use
- New ‘Natural’ antimicrobial proteins based on non-mammalian species
Tony has a special interest in the Benefit-Risk assessment of antimicrobials, and is part of a working party looking at the ethics of the Benefit Risk legislation being adopted in the EU and USA.
